DMPK and myotonic dystrophy type 1: The compound reduced DMPK transcript abundance to a similar extent as Cugamycinin DM1 patient-derived myotubes (∼45% vs ∼55% at 5 μMdosage) and similarly rescued DM1 pre-mRNA splicing defects, whilepossessing a significantly lower molecular weight (Figure S14).